Select Medical(US:SEM)2025-08-13 13:00Financial Performance - Semperit Group's H1 2025 revenue decreased by 72% to EUR 3205 million compared to EUR 3455 million in H1 2024 [23] - EBITDA decreased by 352% to EUR 307 million, with a margin of 96% compared to 137% in H1 2024 [23] - Earnings after tax turned negative to EUR -112 million, compared to a positive EUR 96 million in H1 2024 [6] - Free cash flow decreased by 411% to EUR 139 million [22, 23] - CAPEX decreased by 514% to EUR 185 million [23] Segment Performance - Semperit Industrial Applications (SIA) revenue decreased by 47% to EUR 1336 million [50] - SIA EBITDA decreased by 192% to EUR 242 million, with a margin of 181% [50] - Semperit Engineered Applications (SEA) revenue decreased by 90% to EUR 1869 million [50] - SEA EBITDA decreased by 469% to EUR 147 million, with a margin of 79% [50] Balance Sheet - Cash and cash equivalents stood at EUR 1129 million [6, 22, 38] - Equity ratio was 455% [6, 38] - Net financial debt was EUR 1186 million, with a net financial debt/EBITDA ratio of 17x [22, 38] Outlook - The company confirmed its FY 2025 operational EBITDA guidance of EUR 65 million - EUR 85 million [6, 43] - CAPEX is expected to be around EUR 50 million [43]